Table 1.
Characteristics of the study population
| White non-Hispanic (N=552) | Black (N=108) |
Hispanic (N=154) | P | |
|---|---|---|---|---|
| Male sex | 301 (54.5) | 53 (49.1) | 83 (53.9) | .58 |
| Age at diagnosis | 10.1 (3.7, 14.9) | 11.3 (3.7, 13.4) | 8.9 (2.6, 14.2) | .23 |
| Primary cytogenetic lesion | ||||
| KMT2Ar | 124 (22.5) | 25 (23.1) | 21 (13.6) | .05 |
| t(8;21) | 60 (10.9) | 23 (21.3) | 27 (17.5) | <.01 |
| inv(16) | 75 (14.3) | 11 (10.2) | 22 (15.4) | .46 |
| −7/-7q | 5 (0.9) | 2 (1.9) | 1 (0.6) | .59 |
| −5/-5q | 22 (4.0) | 9 (8.3) | 8 (5.2) | .15 |
| Normal | 139 (25.2) | 17 (15.7) | 28 (18.2) | .04 |
| Other | 133 (24.1) | 35 (32.4) | 47 (30.5) | .088 |
| Unknown | 27 (4.9) | 0 | 11 (7.1) | .024 |
| Prominent mutations | ||||
| FLT3 | 34 (6.2) | 7 (6.6) | 10 (6.5) | .98 |
| NPM1 | 41 (7.4) | 4 (3.7) | 12 (7.8) | .54 |
| CEBPA | 30 (5.4) | 7 (6.5) | 6 (3.9) | .67 |
| cKIT (exon 8) | 22 (4.0) | 7 (6.5) | 4 (2.6) | .11 |
| cKIT (exon 17) | 16 (2.9) | 0 | 6 (3.9) | .08 |
| Treatment protocol | .01 | |||
| AAML0531 | 465 (84.2) | 85 (78.7) | 138 (89.6) | |
| AAML03P1 | 52 (9.4) | 13 (12.0) | 16 (10.4) | |
| CCG-2961 | 35 (6.3) | 10 (9.3) | 0 | |
| WBC at diagnosis (median, IQR) |
31.1 (10.9, 86.7) | 34.2 (15.9, 96.9) | 33.6 (11.8, 90.8) | .34 |
| CNS (+) at diagnosis | 35 (6.3) | 12 (11.1) | 8 (5.2) | .14 |
| MRD at end of course 1 | .07 | |||
| Positive | 133 (24.1) | 33 (30.6) | 32 (20.8) | |
| Negative | 295 (53.4) | 48 (44.4) | 96 (62.3) | |
| Unknown | 124 (22.5) | 27 (25.0) | 26 (16.9) | |
| MRD at end of course 2 | <.01 | |||
| Positive | 66 (12.0) | 15 (13.9) | 21 (13.6) | |
| Negative | 304 (55.1) | 44 (40.7) | 99 (64.3) | |
| Unknown | 182 (33.0) | 49 (45.4) | 34 (22.1) | |
| HSCT received in CR1 | 88 (15.9) | 10 (9.3) | 23 (14.9) | .20 |
Categorical data are n (%); continuous data are median (interquartile range).
CNS, central nervous system; CR1, first complete remission; HSCT, hematopoietic stem cell transplant; MRD, minimal residual disease.